Home > Publications . Search All . Browse All . Country . Browse PSC Pubs . PSC Report Series

PSC In The News

RSS Feed icon

Stephenson says homophobia among gay men raises risk of intimate partner violence

Frey says having more immigrants with higher birth rates fills need in the US

Inglehart's work on the rise of populism cited in NYT

More News

Highlights

Savolainen wins Outstanding Contribution Award for study of how employment affects recidivism among past criminal offenders

Giving Blueday at ISR focuses on investing in the next generation of social scientists

Pfeffer and Schoeni cover the economic and social dimensions of wealth inequality in this special issue

PRB Policy Communication Training Program for PhD students in demography, reproductive health, population health

More Highlights

Next Brown Bag

Mon, Jan 23, 2017 at noon:
H. Luke Shaefer

Measuring the Incremental Cost of Clinical Cancer Research

Archived Abstract of Former PSC Researcher

Goldman, D.P., Michael Schoenbaum, A.L. Potosky, J.C. Weeks, S.H. Berry, J.J. Escarce, B.A. Weidmer, and M.L. Kilgore. 2001. "Measuring the Incremental Cost of Clinical Cancer Research." Journal of Clinical Oncology, 19(1): 105-110.

Purpose: To summarise evidence on the costs of treating patients in clinical trials and to describe the Cost of Cancer Treatment Study, an ongoing effort to produce generalizable estimates of the incremental costs of government-sponsored cancer trials. Methods: A retrospective study of costs will be conducted with 1,500 cancer patients recruited from ct randomly selected sample of institutions in the United States. Patients accrued to either phase II or phase III National Cancer Institute-sponsored clinical trials during a 15-month period will be asked to participate in a study of their health care utilization (n = 750). Costs will be measured approximately 1 year after their trial enrollment from a combination of billing records, medical records, and an in-person survey questionnaire. Similar data will be collected for a comparable group of cancer patients not in trials (n = 750) to provide an estimate of the incremental colt. Results: Evidence suggests insurers limit access to trials because of cost concerns. Public and private efforts are underway to change these policies, but their permanent status is unclear. previous studies found that treatment costs in clinical trials are similar to costs of standard therapy. However, it is difficult to generalize from these studies because of the unique practice settings, insufficient sample sizes, and the exclusion of potentially important costs. Conclusion: Denials of coverage for treatment in a clinical trial limit patient access to trials and could impede clinical research. Preliminary estimates suggest changes to these policies would not be expensive, but these results are not generalizable. The Cost of Cancer Treatment Study is an ongoing effort to provide generalizable estimates of the incremental treatment cost of phase II and phase III cancer trials. The results should be of great interest to insurers and the research community as they consider permanent ways to finance cancer trials. J Clin Oncol 19:105-110. (C) 2001 by American Society of Clinical Oncology.

Browse | Search : All Pubs | Next